Skip to main content
Edition No. 102 · GlobalEst. 2026
S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,810.90+0.55%DAX26,406.61+0.22%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.1006-1.46%GBP/USD1.3195-1.15%Gold3,869.60-0.40%Crude Oil85.36-3.81%Bitcoin64,264.62-5.84%S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,810.90+0.55%DAX26,406.61+0.22%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.1006-1.46%GBP/USD1.3195-1.15%Gold3,869.60-0.40%Crude Oil85.36-3.81%Bitcoin64,264.62-5.84%

University Medical Center Mainz Reports Success in First Clinical Trial of Activated Regulatory T Cells

New cell therapy approach shows promise in preventing graft-versus-host disease following stem cell transplants.

By Planet Earth News Medicine Desk· Published 2026-11-08· 2 min read
Ayoub Chanoufi / Pexels / Pexels
PENN Explainer

Hear this story explained in 90 seconds.

Researchers at the University Medical Center Mainz have announced promising results from the first clinical trial of a new cell therapy designed to prevent graft-versus-host disease. This condition is a common and dangerous complication that can occur after a patient receives a stem cell transplant. The study focused on the use of activated regulatory T cells, known as Tregs, to improve patient outcomes. The findings were recently shared by the research team based in Germany. The therapy, referred to as the ATreg process, was developed by the company ActiTrexx GmbH. Unlike traditional methods that require weeks of laboratory cell growth, this new approach uses a patented activator to stimulate cells in just 16 hours. This rapid production process addresses a major bottleneck in the development of cell-based treatments. By harvesting Tregs from healthy, unrelated donors, the team created a more efficient way to promote immune tolerance. Professor Andrea Tüttenberg, the co-founder and CEO of ActiTrexx, explained that the activation process significantly enhances the natural ability of these cells to prevent rejection. Because the cells are more effective, a smaller number is required for the treatment to work. During the 100-day observation period following transplantation, no patients in the study developed severe Grade 3 or 4 graft-versus-host disease. Furthermore, the researchers reported that no transplant-related deaths occurred among the participants. These results suggest that the therapy could make stem cell transplants safer for a wider range of patients. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice standards. It received approval from the Paul Ehrlich Institute and relevant ethics committees. Funding for the development of the ATreg procedure was provided by the Federal Ministry of Education and Research through the GO-Bio program. This initial Phase I trial involved a small group of patients, but the results provide a foundation for future research. The team believes that this approach could eventually simplify the search for suitable donors by reducing the need for a perfect genetic match. As the medical community continues to explore this new generation of cell therapies, the focus will remain on refining the process for larger clinical applications.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine